Supplementary Tables 1-3 and Figures 1-9 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes

This file contains the following supplemental data: Supplemental Table 1. Specific information for MTT cell viability assays with single agents. Supplemental Table 2. Patient characteristics of synovial sarcoma cohort. Supplemental Table 3. Specifications of antibodies used for IHC and Western Blot. Supplemental Table 6. Summary of SS cell line sensitivity to specific tyrosine kinase inhibitors. Supplemental Figure 1. Integrated protein-protein interaction network for all sarcoma subgroups. Supplemental Figure 2. ALK expression and phosphorylation in ES and RMS cell lines. Supplemental Figure 3. Schematic representation of ALK exon 2-17 deletion in Aska-SS cells. Supplemental Figure 4. Deglycosylation of ALK in Aska-SS cells. Supplemental Figure 5. SS cell line sensitivity to foretinib, gefitinib and erlotinib. Supplemental Figure 6. Effects of ALK inhibition on cell cycle and apoptotic markers in Aska-SS cells. Supplemental Figure 7. Effects of ALK inhibition on Aska-SS in vivo tumors. Supplemental Figure 8. ALK, MET and PDGFRA mRNA expression in clinical SS versus other STS samples. Supplemental Figure 9. ALK IHC and patient characteristics of ALK-positive SS tumors. Supplemental Figure 10. Effect of PDGFR and MET inhibition on apoptosis in Yamato-SS cells. Brief sections of Supplementary methods and Supplementary references are included in this file as well.